EPIA formed to quantify flu burden in children

17 May 2009

The Netherlands Institute for Health Services Research and SDI, a US private-sector health care information company, have formed the European  Pediatric Influenza Analysis group, created to generate data needed to  inform the decision process about pediatric influenza vaccination policy  in individual European countries. Researchers from Denmark, England,  Finland, Italy, the Netherlands, Scotland, Spain and Wales are  participating; it is hoped that other countries will also join.

The EPIA was formed to address knowledge gaps highlighted in a recent  European Center for Disease Prevention and Control (ECDC) report that  concluded that a key barrier to decision-making about pediatric flu  vaccines is the lack of high-quality, European-specific data on disease  burden, especially for young children. It is estimated by the ECDC that  at least 40,000 people die each year from influenza in the European  Union. The EPIA will present the initial results from their research  project at the 27th annual meeting of the European Society for Pediatric  Infectious Diseases in June.

In the 2006 European Journal of Pediatrics article, titled Should  healthy children be vaccinated against influenza?, Terho Heikkinen and  colleagues noted: "in many European and other countries, the discussion  about potential expansion of target groups for annual influenza  vaccination has just started...the development of new vaccination  strategies in any country will require careful evaluation of the  benefits and disadvantages of the intervention with respect to local  factors."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight